<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00951106</url>
  </required_header>
  <id_info>
    <org_study_id>WRAIR #719</org_study_id>
    <nct_id>NCT00951106</nct_id>
  </id_info>
  <brief_title>Therapeutic Efficacy Study of Pyrimethamine/Sulfdoxine (Fansidar速) for the Treatment of Uncomplicated Falciparum Malaria in the Peruvian Amazon</brief_title>
  <official_title>Therapeutic Efficacy Study of Pyrimethamine / Sulfdoxine (Fansidar速) for the Treatment of Uncomplicated Falciparum Malaria in the Peruvian Amazon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walter Reed Army Institute of Research (WRAIR)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of pyrimethamine/sulfdoxine
      (Fansidar速) for the treatment of uncomplicated falciparum malaria in the Peruvian Amazon.
      Reports in the mid 1990s indicated that Fansidar was failing to cure patients with confirmed
      falciparum malaria. The study design was based on accepted WHO parasitological and clinical
      outcomes to determine the overall efficacy of Fansider and inform the Peruvian National
      Malaria Control authorities as to the continued wisdom of recommending Fansidar as first line
      treatment for uncomplicated falciparum malaria in the Peruvian Amazon.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1998</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">June 1999</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the efficacy of pyrimethamine/sulfdoxine (Fansidar) for the treatment of uncomplicated falciparum malaria in the Peruvian Amazon.</measure>
    <time_frame>28 days after dose</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Malaria, Vivax</condition>
  <condition>Malaria, Falciparum</condition>
  <arm_group>
    <arm_group_label>Pyrimethamine/sulfdoxine (Fansidar)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pyrimethamine/sulfdoxine (Fansidar)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrimethamine/sulfdoxine (Fansidar)</intervention_name>
    <arm_group_label>Pyrimethamine/sulfdoxine (Fansidar)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pf monoinfection with asexual forms

          -  Parasite density of greater than 500 per mcl and less than 200 parasites per oil
             immersion field (MINSA quantification of &quot;4 plus&quot;)

          -  Age &gt; 6 months

          -  Temperature greater than 38C (101F)

          -  Available and willing to return for follow-up

        Exclusion Criteria:

          -  Presence of any of the following &quot;danger&quot; signs or symptoms suggestive of severe
             malaria

          -  Not able to drink or breastfeed

          -  Repeated vomiting (unable to keep anything down)

          -  Convulsions during present illness

          -  Lethargic or unconscious state

          -  Unable to sit or stand up

          -  Respiratory distress

          -  Jaundice (observation) or dark urine (by history)

          -  Severe anemia (Hemoglobin &lt; 5 g/dl)

          -  Hypotension (systolic BP &lt; 80 mm Hg in adults and &lt; 50 mm Hg in children under the age
             of 5

          -  Presence of another significant illness or chronic disease

          -  Known pregnancy (by history)

          -  History of hypersensitivity to medication used in the test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Magill, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Institute of Research (WRAIR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Naval Medical Research Center Detachment</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <results_reference>
    <citation>Magill AJ, Zegarra J, Garcia C, Marqui単o W, Ruebush TK 2nd. Efficacy of sulfadoxine-pyrimethamine and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon basin of Peru. Rev Soc Bras Med Trop. 2004 May-Jun;37(3):279-81.</citation>
    <PMID>15330070</PMID>
  </results_reference>
  <results_reference>
    <citation>Huaman MC, Roncal N, Nakazawa S, Long TT, Gerena L, Garcia C, Solari L, Magill AJ, Kanbara H. Polymorphism of the Plasmodium falciparum multidrug resistance and chloroquine resistance transporter genes and in vitro susceptibility to aminoquinolines in isolates from the Peruvian Amazon. Am J Trop Med Hyg. 2004 May;70(5):461-6.</citation>
    <PMID>15155976</PMID>
  </results_reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2009</study_first_submitted>
  <study_first_submitted_qc>August 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2009</study_first_posted>
  <last_update_submitted>July 26, 2010</last_update_submitted>
  <last_update_submitted_qc>July 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>COL Alan Magill</name_title>
    <organization>WRAIR</organization>
  </responsible_party>
  <keyword>Peru</keyword>
  <keyword>Sulfadoxine-pyrimethamine</keyword>
  <keyword>Drug resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
    <mesh_term>Malaria, Vivax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

